Jailendra Singh
Stock Analyst at Truist Securities
(0.76)
# 4,012
Out of 5,182 analysts
195
Total ratings
22.94%
Success rate
-28.2%
Average return
Main Sectors:
Stocks Rated by Jailendra Singh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHR Phreesia | Downgrades: Hold | $24 → $11 | $8.37 | +31.42% | 8 | Mar 31, 2026 | |
| ASTH Astrana Health | Maintains: Buy | $37 → $38 | $25.05 | +51.70% | 6 | Mar 13, 2026 | |
| VEEV Veeva Systems | Reiterates: Buy | $275 → $262 | $173.98 | +50.59% | 8 | Mar 5, 2026 | |
| PGNY Progyny | Maintains: Buy | $34 → $28 | $16.60 | +68.67% | 11 | Mar 2, 2026 | |
| PRVA Privia Health Group | Maintains: Buy | $31 → $33 | $21.21 | +55.59% | 9 | Mar 2, 2026 | |
| EVH Evolent Health | Maintains: Buy | $10 → $6 | $2.25 | +166.67% | 9 | Feb 26, 2026 | |
| HIMS Hims & Hers Health | Reiterates: Hold | $37 → $18 | $19.14 | -5.96% | 12 | Feb 24, 2026 | |
| IQV IQVIA Holdings | Maintains: Buy | $290 → $245 | $173.26 | +41.41% | 19 | Feb 19, 2026 | |
| WAY Waystar Holding | Maintains: Buy | $51 → $38 | $23.74 | +60.07% | 4 | Feb 18, 2026 | |
| MEDP Medpace Holdings | Maintains: Hold | $555 → $539 | $498.34 | +8.16% | 7 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $62 → $37 | $22.77 | +62.49% | 10 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $52 | $44.28 | +17.43% | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $231 → $222 | $114.19 | +94.41% | 11 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $22 | $9.44 | +133.17% | 1 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $38.98 | +23.14% | 1 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $10 → $9 | $5.27 | +70.78% | 16 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6.5 → $5.5 | $2.05 | +168.29% | 12 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $12 → $7.5 | $5.50 | +36.36% | 7 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $14 | $10.65 | +31.46% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $160 → $163 | $10.74 | +1,413.04% | 8 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $13 | $1.26 | +931.75% | 11 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $24 | $1.08 | +2,122.22% | 2 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $4 | $0.60 | +561.38% | 4 | Feb 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $58 | $214.05 | -72.90% | 2 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $90 → $45 | $1.28 | +3,429.41% | 7 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $230 → $333 | $884.28 | -62.34% | 6 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $9 | $1.72 | +423.26% | 2 | May 19, 2021 |
Phreesia
Mar 31, 2026
Downgrades: Hold
Price Target: $24 → $11
Current: $8.37
Upside: +31.42%
Astrana Health
Mar 13, 2026
Maintains: Buy
Price Target: $37 → $38
Current: $25.05
Upside: +51.70%
Veeva Systems
Mar 5, 2026
Reiterates: Buy
Price Target: $275 → $262
Current: $173.98
Upside: +50.59%
Progyny
Mar 2, 2026
Maintains: Buy
Price Target: $34 → $28
Current: $16.60
Upside: +68.67%
Privia Health Group
Mar 2, 2026
Maintains: Buy
Price Target: $31 → $33
Current: $21.21
Upside: +55.59%
Evolent Health
Feb 26, 2026
Maintains: Buy
Price Target: $10 → $6
Current: $2.25
Upside: +166.67%
Hims & Hers Health
Feb 24, 2026
Reiterates: Hold
Price Target: $37 → $18
Current: $19.14
Upside: -5.96%
IQVIA Holdings
Feb 19, 2026
Maintains: Buy
Price Target: $290 → $245
Current: $173.26
Upside: +41.41%
Waystar Holding
Feb 18, 2026
Maintains: Buy
Price Target: $51 → $38
Current: $23.74
Upside: +60.07%
Medpace Holdings
Feb 11, 2026
Maintains: Hold
Price Target: $555 → $539
Current: $498.34
Upside: +8.16%
Feb 6, 2026
Maintains: Buy
Price Target: $62 → $37
Current: $22.77
Upside: +62.49%
Jan 12, 2026
Initiates: Buy
Price Target: $52
Current: $44.28
Upside: +17.43%
Jan 8, 2026
Downgrades: Hold
Price Target: $231 → $222
Current: $114.19
Upside: +94.41%
Jan 8, 2026
Upgrades: Buy
Price Target: $12 → $22
Current: $9.44
Upside: +133.17%
Jun 16, 2025
Initiates: Buy
Price Target: $48
Current: $38.98
Upside: +23.14%
May 27, 2025
Maintains: Hold
Price Target: $10 → $9
Current: $5.27
Upside: +70.78%
Apr 10, 2025
Maintains: Hold
Price Target: $6.5 → $5.5
Current: $2.05
Upside: +168.29%
Apr 10, 2025
Maintains: Hold
Price Target: $12 → $7.5
Current: $5.50
Upside: +36.36%
Jul 2, 2024
Maintains: Buy
Price Target: $17 → $14
Current: $10.65
Upside: +31.46%
May 24, 2024
Maintains: Hold
Price Target: $160 → $163
Current: $10.74
Upside: +1,413.04%
May 4, 2022
Maintains: Neutral
Price Target: $16 → $13
Current: $1.26
Upside: +931.75%
Feb 24, 2022
Maintains: Neutral
Price Target: $30 → $24
Current: $1.08
Upside: +2,122.22%
Feb 8, 2022
Downgrades: Neutral
Price Target: $14 → $4
Current: $0.60
Upside: +561.38%
Feb 4, 2022
Maintains: Neutral
Price Target: $60 → $58
Current: $214.05
Upside: -72.90%
Jan 7, 2022
Downgrades: Underperform
Price Target: $90 → $45
Current: $1.28
Upside: +3,429.41%
Jan 7, 2022
Upgrades: Outperform
Price Target: $230 → $333
Current: $884.28
Upside: -62.34%
May 19, 2021
Maintains: Neutral
Price Target: $10 → $9
Current: $1.72
Upside: +423.26%